ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing innovative medicines to address unmet medical needs in central nervous system disorders. Their flagship product, NUPLAZID, is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA is also working on a pipeline of product candidates for other neurological and psychiatric disorders, such as dementia-related psychosis, schizophrenia, and major depressive disorder. The company is dedicated to advancing science and improving the lives of patients and their families affected by these debilitating diseases. ACADIA is headquartered in San Diego, California, and has operations in the United States and Europe.